|
Jul 7
|
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
|
|
Jul 7
|
Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating
|
|
Jul 4
|
Village Farms International And 2 Other Promising Penny Stocks For Your Watchlist
|
|
Jun 30
|
We're Interested To See How AbCellera Biologics (NASDAQ:ABCL) Uses Its Cash Hoard To Grow
|
|
Jun 25
|
AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology
|
|
May 10
|
AbCellera Biologics First Quarter 2025 Earnings: Revenues Disappoint
|
|
May 9
|
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
|
|
May 9
|
Q1 2025 Abcellera Biologics Inc Earnings Call
|
|
May 9
|
AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...
|
|
May 8
|
AbCellera Reports Q1 2025 Business Results
|
|
Apr 3
|
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
|
|
Feb 20
|
US Penny Stocks To Watch In February 2025
|
|
Feb 18
|
One AbCellera Biologics Insider Raised Their Stake In The Previous Year
|
|
Jan 22
|
3 Promising US Penny Stocks With Market Caps Under $900M
|
|
Jan 21
|
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
|
|
Jan 20
|
AbCellera Biologics Inc. (NASDAQ:ABCL) most popular amongst individual investors who own 36% of the shares, institutions hold 29%
|
|
Jan 17
|
AbCellera Biologics Inc. (ABCL): A Bull Case Theory
|
|
Jan 15
|
AbbVie and Simcere Zaiming link to develop trispecific antibody
|
|
Sep 26
|
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
|
|
Aug 29
|
AbCellera to Present at Upcoming Investor Conferences in September
|